Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Methotrexate vs Dactinomycin for Low-Risk Gestational Trophoblastic Neoplasia
NCT00003702Phase 3Completed
- Sponsor
- GOG Foundation
- Start
- Jun 1999
- Primary completion
- Jul 2010
- Modality
- DNA Intercalators/Alkylators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in gestational trophoblastic neoplasia (GTN) comparing Methotrexate with Dactinomycin (2 arms). Primary endpoints: Response Based on Blood Human Chorionic Gonadotropin (hCG) Assay up to 12 months and Incidence of Adverse Effects (Grade 3 or Higher) up to 12 months. Started Jun 1999; status: completed.
02
Drugs
methotrexateactinomycin D
03
Conditions
gestational trophoblastic neoplasia (GTN)
Beyond the preview
Go deeper on NCT00003702.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00003702.